Welcome to our dedicated page for Ligand Pharma SEC filings (Ticker: LGND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ligand Pharmaceuticals Inc. (NASDAQ: LGND) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8‑K and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Ligand’s royalty‑focused biopharmaceutical business, financing activities and material agreements that support its model of funding mid‑ to late‑stage drug development, purchasing royalty rights and licensing technology platforms.
Ligand’s recent 8‑K filings describe events such as the completion of a private offering of 0.75% convertible senior notes due 2030, amendments to its credit agreement with Citibank, N.A., and the entry into material definitive agreements. Other 8‑Ks report quarterly financial results, including revenue composition and non‑GAAP measures, and discuss transactions like royalty financing agreements and the closing of a merger involving a Ligand subsidiary that became part of Pelthos Therapeutics. Filings also confirm that Ligand’s common stock trades on The Nasdaq Global Market under the symbol LGND and identify Jupiter, Florida as the location of its principal executive offices.
On Stock Titan, these SEC filings are paired with AI‑powered summaries designed to make complex regulatory language more accessible. Annual reports on Form 10‑K and quarterly reports on Form 10‑Q can be reviewed for discussions of Ligand’s business model, risk factors and segment information, while current reports on Form 8‑K highlight specific material events such as financings, credit facility amendments and significant portfolio transactions. Insider transaction reports on Form 4, when available, provide visibility into equity transactions by directors and officers.
Real‑time updates from EDGAR ensure that new LGND filings appear promptly, and AI analysis helps explain how each document relates to Ligand’s strategy of building diversified royalty and technology revenue streams. This combination allows investors and researchers to move efficiently from raw filings to a clearer understanding of the company’s regulatory and financial disclosures.
Ligand Pharmaceuticals director John W. Kozarich reported multiple small open‑market sales of company common stock. On January 2, 2026, he sold an aggregate of 467 shares in a series of transactions at weighted‑average prices ranging from $186.59 to $192.395 per share.
The filing shows these trades were executed under a pre‑arranged written trading plan adopted on March 7, 2025 in accordance with Rule 10b5‑1, which is designed to allow insiders to sell shares according to a set schedule. After these sales, Kozarich directly beneficially owns 43,654 shares of Ligand common stock.
Ligand Pharmaceuticals’ Chief Financial Officer, Octavio Espinoza, reported multiple stock option exercises on December 16, 2025. He acquired a total of 2,381 shares of common stock through option exercises at strike prices of
Ligand Pharmaceuticals filed an update explaining that it has posted materials about its private placement investment in Athira Pharma, Inc. on its investor relations website and certain social media accounts. These posts provide more detail on the investment for interested readers.
The company also reiterates how it shares important information with the public. Ligand states that material updates may appear through SEC filings, its investor relations site, press releases, public conference calls, webcasts, its X (Twitter) account @Ligand_LGND and its LinkedIn page. Investors and other stakeholders are encouraged to review these channels regularly, and any changes to this list will be updated on the investor relations page.
Ligand Pharmaceuticals reported an insider stock sale by its chief financial officer, Octavio Espinoza. In the transaction dated 12/12/2025, he sold 1,804 shares of the company’s common stock at a price of $188.31 per share, coded as a sale in the regulatory report.
Following this transaction, Espinoza beneficially owns 26,186 shares of Ligand Pharmaceuticals common stock in direct ownership. The report is filed as an individual filing by one reporting person in his capacity as an officer and chief financial officer.
Ligand Pharmaceuticals Inc. Chief Executive Officer and director Todd C. Davis reported a bona fide gift of 130 shares of common stock on 12/04/2025.
The shares were given to a charitable entity and are reported at a price of $0.0, reflecting the gift nature of the transaction. Following this transfer, Davis directly beneficially owns 161,337 shares of Ligand common stock.
Ligand Pharmaceuticals (LGND) director John L. LaMattina reported same‑day option exercises and share sales. On 11/07/2025, he exercised 2,145 options at $66.13 and 2,034 options at $69.51, then sold 2,145 shares at $205.45 and 2,034 shares at $205.45. Following these transactions, he directly owned 30,724 shares. The options exercised were previously granted awards that had been adjusted in connection with the OmniAb Inc. separation and carried expiration dates of 05/25/2027 and 05/23/2026.
Ligand Pharmaceuticals (LGND) reported a strong Q3 2025. Total revenues and other income rose to $115.5 million from $51.8 million, led by royalties of $46.6 million and $58.2 million of contract revenue and other income.
Operating income improved to $54.9 million from $3.1 million, and non‑operating items added $86.2 million, including gains from equity‑method and other investments. Net income reached $117.3 million versus a loss a year ago, with diluted EPS of $5.68. Results included $53.1 million of income from the Pelthos transaction and higher royalties from products such as Filspari, Ohtuvayre, and Capvaxive.
The balance sheet expanded: cash and cash equivalents were $139.4 million and short‑term investments $525.1 million. The company issued $460.0 million of 2030 convertible senior notes, with $445.5 million reported as long‑term notes at quarter‑end. R&D expense increased to $21.0 million, reflecting portfolio activity. Stockholders’ equity rose to $950.2 million.
Ligand Pharmaceuticals (LGND) announced quarterly results by issuing a press release covering its financial performance for the three and nine months ended September 30, 2025.
The press release is furnished as Exhibit 99.1 and, in line with General Instruction B.2., the information is furnished rather than filed, which limits its treatment under the Exchange Act.
Ligand Pharmaceuticals (LGND): Form 4 insider transaction
Director John W. Kozarich reported open‑market sales of Ligand common stock on 11/03/2025 pursuant to a Rule 10b5‑1 trading plan adopted on March 07, 2025. Reported sales were executed in multiple trades: 84 shares at a weighted‑average price of $188.9968, 49 shares at $190.2579, 207 shares at $191.2494, and 127 shares at $192.3781. Following these transactions, the reporting person beneficially owned 44,588 shares, held directly. Prices reflect weighted averages across multiple executions within disclosed ranges.
Ligand Pharmaceuticals (LGND) reported an insider transaction by director John W. Kozarich. On 10/01/2025, he executed multiple open-market sales of common stock under a Rule 10b5-1 trading plan adopted on March 07, 2025.
Sales were small blocks of 24, 196, 155, and 92 shares at weighted-average prices of $177.6048, $178.4051, $180.0098, and $181.1838, respectively. Following these transactions, he directly beneficially owned 45,055 shares.
Footnotes state the prices reflect weighted averages across multiple trades within disclosed price ranges, with full breakdowns available upon request. The filing lists the reporting person as a Director with direct ownership.
FAQ
What is the current stock price of Ligand Pharma (LGND)?
What is the market cap of Ligand Pharma (LGND)?
